nCounter® Neuropathology Panel
Helping Your Research
Biomarker discovery and signature development are essential for identification of novel therapies and for earlier detection and development of therapies for neurodegenerative disorders like Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). The nCounter Neuropathology Panel helps perform comprehensive multiplex gene expression analysis in human or mouse samples with genes involved in six fundamental themes of neurodegeneration: neurotransmission, neuron-glia interaction, neuroplasticity, cell structure integrity, neuroinflammation, and metabolism.
- Developed for research of Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Huntington’s Disease, and other neurological disorders
- Includes unique cell typing feature for measuring the abundance of five important CNS cell types, including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells
How It Works
nCounter Neuropathology Panels utilize NanoString’s unique barcoding technology and the nCounter Analysis System to help accelerate your research.
Screen 770 genes specific for neurodegeneration
Comprehensively Assess 23 pathways
Monitor progression of neurodegeneration
Screen potential therapeutics
Discover biomarkers and develop signatures associated with neurodegeneration
Customize with up to 55 additional user-defined genes with the Panel Plus option
Get data quickly with a streamlined, user-friendly, and efficient workflow with only 15 minutes hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Genes included in the Neuropathology Panels provide unique cell profiling data for measuring the abundance1 of five important cell types including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells. The table below summarizes each cell type represented in the panels along with the gene content qualified through current literature references.
1Danaher P. et al. Gene expression markers of Tumor Infiltrating Leukocytes JITC 2017
Functional annotations for 23 fundamental pathways and processes were assigned across all genes in the Neuropathology Panels allowing for a practical view of important aspects of the onset and progression of neurodegenerative disease.
Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
The majority of supratentorial ependymomas in children contain oncogenic fusions, such as ZFTA-RELA or YAP1-MAMLD1. In contrast, posterior fossa (PF) ependymomas lack recurrent somatic mutations and are classified based on gene expression or methylation profiling into group A (PFA) and group B (PFB).
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study.
The ability to investigate therapeutic interventions in animal models of neurodegenerative diseases depends on extensive characterization of the model(s) being used. There are numerous models that have been generated to study Alzheimer’s disease (AD) and the underlying pathogenesis of the disease.
Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT).
Purpose: Atypical teratoid/rhabdoid tumor (AT/RT) is arising typically in young children and is associated with a dismal prognosis which there is currently no curative chemotherapeutic regimen. Based on previous studies showing high histone deacetylase 1 (HDAC1) expression in AT/RT, the HDAC1 inhibitor CI-994 was used as a novel treatment strategy in this study.